99mTc-sestamibi

Figure 7.12 (A) 99mTc-sestamibi (Cardiolite ) and (B) "mTc-tetrofosmin (Myoview ).

Maffioh L, Steens J, Pauwels E and Bombardieri E. Applications of 99mTc-sestamibi in oncology. Tumori 1996 82 12-21. 

Hexakis(2-methoxyisobutylisonitrile)technetium-99m (commonly known as [99mTc]Sestamibi) (20a), although originally developed as a radiopharmaceutical for myocardial perfusion imaging [59,60], was the first metal complex 

Bacher-Stier C, Sharir T, Kavanagh PB, et al. Postexercise lung uptake of 99mTc-sestamibi determined by a new automatic technique validation and application in detection of severe and extensive coronary artery disease and reduced left ventricular function. J Nucl Med 2000 41(7) 1190-7. 

Doukaki S, Arico M, Bongiorno MR. Erythroderma related to the administration of 99mTc-sestamibi the first report. J NucI Cardiol 2010 17 520-2. 

Miller TD, Christian TF, Hopfenspirger MR, et al. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995 92(3) 334-41. 

Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, Bacharach SL et al. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]-fluorodeoxyglucose. Circulation 1994 89 578-587 

Several clinical studies have shown the feasibility of interrogating Pgp transport activity in vivo with imaging cameras commonly available in nuclear medicine facilities [71-73,124-129]. In general, 99mTc-Sestamibi pharmacokinetic data are extracted from tumor images over time and correlated with immuno- 

---